ea0081p25 | Adrenal and Cardiovascular Endocrinology | ECE2022
Diaz Catalan Daniela
, Beyhart Arturo
, Mora Mireia
, Rodrigo Maite
, Boswell Laura
, Casals Gregori
, Alexandra Hanzu Felicia
Objective: After Cushing Syndrome (CS) is cured, up to 70% of patients develop chronic adrenal insufficiency (AI) and hypothalamus-pituitary-adrenal (HPA) axis dysfunction. A long-term treatment with glucocorticoids (GC) is mandatory to overcome AI. However, this treatment implies non-desired complications. Fibroblast growth factor (FGF21), a key regulator of metabolism, has a bidirectional relationship with GC that bypasses the negative feedback of the HPA axis. In this study...